Fischer Benedikt, Oviedo-Joekes Eugenia, Blanken Peter, Haasen Christian, Rehm Jürgen, Schechter Martin T, Strang John, van den Brink Wim
Centre for Addictions Research of British Columbia, University of Victoria, Victoria, Canada.
J Urban Health. 2007 Jul;84(4):552-62. doi: 10.1007/s11524-007-9198-y.
Since the initial Swiss heroin-assisted treatment (HAT) study conducted in the mid-1990s, several other jurisdictions in Europe and North America have implemented HAT trials. All of these studies embrace the same goal-investigating the utility of medical heroin prescribing for problematic opioid users-yet are distinct in various key details. This paper briefly reviews (initiated or completed) studies and their main parameters, including primary research objectives, design, target populations, outcome measures, current status and-where available-key results. We conclude this overview with some final observations on a decade of intensive HAT research in the jurisdictions examined, including the suggestion that there is a mounting onus on the realm of politics to translate the-largely positive-data from completed HAT science into corresponding policy and programming in order to expand effective treatment options for the high-risk population of illicit opioid users.
自20世纪90年代中期开展首项瑞士海洛因辅助治疗（HAT）研究以来，欧洲和北美的其他几个司法管辖区也进行了HAT试验。所有这些研究都有相同的目标——调查为有问题的阿片类药物使用者开具医用海洛因的效用——但在各个关键细节上有所不同。本文简要回顾了（已启动或已完成的）研究及其主要参数，包括主要研究目标、设计、目标人群、结果指标、现状以及（如有）关键结果。我们在本综述结尾对在所研究的司法管辖区内进行的十年密集HAT研究发表了一些最终看法，包括提出政界有越来越大的责任将已完成的HAT科学研究中大体上呈阳性的数据转化为相应的政策和项目，以便为非法阿片类药物使用者这一高危人群扩大有效的治疗选择。
